Sun Phar­ma tem­porar­i­ly halts ship­ments from man­u­fac­tur­ing plant af­ter FDA let­ter

Sun Phar­ma is paus­ing pro­duc­tion at one of its plants in In­dia af­ter fac­ing scruti­ny by US reg­u­la­tors over nec­es­sary cor­rec­tive work.

In a let­ter to the Na­tion­al Stock Ex­change of In­dia dat­ed Sun­day, Sun Phar­ma said it had been hand­ed a let­ter from the FDA ti­tled, “Con­sent De­cree Cor­re­spon­dence/Non-Com­pli­ance Let­ter.” US reg­u­la­tors con­veyed to Sun Phar­ma that it needs to take cor­rec­tive ac­tions at the man­u­fac­tur­ing fa­cil­i­ty in the city of Mo­hali, In­dia, in the Pun­jab re­gion, be­fore Sun can ship any prod­ucts to the US.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN